BioTuesdays

Tag - Naureen Quibria

Markets

Maxim starts Oncternal at buy; PT $3.50

Maxim Group initiated coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and price target of $3.50. The stock closed at 99 cents on May 9. Oncternal is a clinical-stage company focused on novel targets...

May 10, 2022
ayala logo
Markets

Maxim lowers Ayala Pharma PT to $12 from $22

Maxim Group reduced its price target for Ayala Pharmaceuticals (NASDAQ:AYLA) to $12 from $22, but maintained a “buy” rating, after the company discontinued the Phase 2 TENANCITY trial evaluating AL101 in triple negative...

March 30, 2022
Markets

Maxim starts Genenta Science at buy; PT $21

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12. Genenta is developing cancer therapeutics using an autologous ex...

January 13, 2022
ayala logo
Markets

Maxim starts Ayala at buy; PT $22

Maxim Group initiated coverage of Ayala Pharmaceuticals (NASDAQ:AYLA) with a “buy” rating and $22 price target. The stock closed at $9 on Dec. 17. Ayala is developing two gamma-secretase inhibitors – AL101 and...

December 20, 2021
Kazia Therapeutics New
Markets

Maxim starts Kazia Therapeutics at buy; PT $18

Maxim Group initiated coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and $18 price target. The stock closed at $10.71 on Oct. 13. Kazia is developing two oncology drug candidates: paxalisib, for brain...

October 14, 2021
Immutep Logo
Markets

Maxim transfers coverage of Immutep at buy; PT $8

Maxim Group transferred primary coverage of Immutep (NASDAQ:IMMP) to analyst, Naureen Quibria, Ph.D., with a “buy” rating and $8 price target. The stock closed at $3.53 on July 15.  Immutep has a pipeline of...

July 16, 2021
OSE Immunotherapeutics
Markets

Maxim starts OSE Immunotherapeutics at buy; PT $22

Maxim Group initiated coverage of OSE Immunotherapeutics (NXT PA:OSE) with a “buy” rating and $22 price target. The stock closed at $13.56 on June 22. Analyst Naureen Quibria, Ph.D., writes that French-based OSE has a...

June 23, 2021
Oncorus-Logo
Markets

Maxim starts Oncorus at buy; PT $35

Maxim Group initiated coverage of Oncorus (NASDAQ:ONCR) with a “buy” rating and price target of $35. The stock closed at $16.39 on March 15. Oncorus is developing oncolytic viral (OV) immunotherapies for solid tumors...

March 16, 2021